Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 209

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

Open access
Szabados, Bernadett, Kockx, Mark, Assaf, Zoe June, van Dam, Pieter-Jan, Rodriguez-Vida, Alejo, Duran, Ignacio, Crabb, Simon J., Van Der Heijden, Michiel S., Pous, Albert Font, Gravis, Gwenaelle, Herranz, Urbano Anido, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Mendez, Maria Jose, Suarez, Cristina, Linch, Mark, Prendergast, Aaron, Tyson, Charlotte, Stanoeva, Diana, Daelemans, Sofie, Rombouts, Miche, Mariathasan, Sanjeev, Tea, Joy S., Mousa, Kelly, Sharma, Shruti, Aleshin, Alexey, Banchereau, Romain, Castellano, Daniel, Powles, Thomas · 2022 · European Urology

Abstract

BACKGROUND Neoadjuvant immunotherapies hold promise in muscle-invasive bladder cancer (MIBC). OBJECTIVE To report on 2-yr disease-free (DFS) and overall (OS) survival including novel tissue-based biomarkers and circulating tumor DNA (ctDNA) in the ABACUS trial. DESIGN, SETTING, AND PARTICIPANTS ABACUS was a multicenter, single-arm, neoadjuvant, phase 2 trial, including patients with MIBC (T2-4aN0M0) who were ineligible for or refused neoadjuvant cisplatin-based chemotherapy. INTERVENTION Two cycles of atezolizumab were given prior to radical cystectomy. Serial tissue and blood samples were collected. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS The primary endpoints of pathological complete response (pCR) rate and dynamic changes to T-cell biomarkers were published previously. Secondary outcomes were 2-yr DFS and OS. A biomarker analysis correlated with relapse-free survival (RFS) was performed, which includes FOXP3, major histocompatibility complex class I, CD8/CD39, and sequential ctDNA measurements. RESULTS AND LIMITATIONS The median follow-up time was 25 mo (95% confidence interval [CI] 25-26). Ninety-five patients received at least one cycle of atezolizumab. Eight patients did not undergo cystectomy (only one due to disease progression). The pCR rate was 31% (27/88; 95% CI 21-41). Two-year DFS and OS were 68% (95% CI 58-76) and 77% (95% CI 68-85), respectively. Two-year DFS in patients achieving a pCR was 85% (95% CI 65-94). Baseline PD-L1 and tumor mutational burden did not correlate with RFS (hazard ratio [HR] 0.60 [95% CI 0.24-1.5], p = 0.26, and 0.72 [95% CI 0.31-1.7], p = 0.46, respectively). RFS correlated with high baseline stromal CD8+ (HR 0.25 [95% CI 0.09-0.68], p = 0.007) and high post-treatment fibroblast activation protein (HR 4.1 [95% CI 1.3-13], p = 0.01). Circulating tumor DNA positivity values at baseline, after neoadjuvant therapy, and after surgery were 63% (25/40), 47% (14/30), and 14% (five/36), respectively. The ctDNA status was highly prognostic at all time points. No relapses were observed in ctDNA-negative patients at baseline and after neoadjuvant therapy. The lack of randomization and exploratory nature of the biomarker analysis are limitations of this work. CONCLUSIONS Neoadjuvant atezolizumab in MIBC is associated with clinical responses and high DFS. CD8+ expression and serial ctDNA levels correlated with outcomes, and may contribute to personalized therapy in the future. PATIENT SUMMARY We showed that bladder cancer patients receiving immunotherapy followed by cystectomy have good long-term outcomes. Furthermore, we found that certain biological features can predict patients who might have particular benefit from this therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2022.04.013

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 209

Metadata

Authors
Szabados, B., Kockx, M., Assaf, Z. J., van Dam, P.-J., Rodriguez-Vida, A., Duran, I., Crabb, S. J., Van Der Heijden, M. S., Pous, A. F., Gravis, G., Herranz, U. A., Protheroe, A., Ravaud, A., Maillet, D., Mendez, M. J., Suarez, C., Linch, M., Prendergast, A., Tyson, C., Stanoeva, D., Daelemans, S., Rombouts, M., Mariathasan, S., Tea, J. S., Mousa, K., Sharma, S., Aleshin, A., Banchereau, R., Castellano, D., & Powles, T.
Venue
European Urology
Publisher
Elsevier BV
Published
2022-08
Volume
82
Issue
2
Pages
212-222
ISSN
0302-2838 (ISSN-L)
OpenAlex
W4280556573
Cited by
209
References
6
FWCI
34.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. https://app.cochat.ai/papers/10.1016/j.eururo.2022.04.013
The paper
Szabados, B., Kockx, M., Assaf, Z. J., van Dam, P.-J., Rodriguez-Vida, A., Duran, I., Crabb, S. J., Van Der Heijden, M. S., Pous, A. F., Gravis, G., Herranz, U. A., Protheroe, A., Ravaud, A., Maillet, D., Mendez, M. J., Suarez, C., Linch, M., Prendergast, A., Tyson, C., . . . Powles, T. (2022). Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. European Urology. https://doi.org/10.1016/j.eururo.2022.04.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.